Shimizu Toshio

シミズトシオ | Shimizu Toshio

Affiliation and department：
Job title： Professor

Research field (1)： Tumor diagnostics and therapeutics

Research keywords (3)：第I相試験 , 新薬開発 , 臨床腫瘍学

Research theme for competitive and other funds (3)：

2022 - 2025 進行癌に対する次世代抗体薬投与時サイトカインプロファイル緊急網羅的解析モデル探索
2017 - 2019 <領域1-1>がんの最適医療(Precision Medicine)の実現に資するゲノム異常及びバイオマーカーの同定と臨床的有用性の検証がん薬物療法におけるexceptional responseをもたらす遺伝子異常の研究と治療開発
2012 - 2015 進行非小細胞肺癌を対象としたエルロチニブとYM155の分子標的治療薬併用第I相試験

Papers (96)：

Noboru Yamamoto, Takafumi Koyama, Jun Sato, Tatsuya Yoshida, Kazuki Sudo, Satoru Iwasa, Shunsuke Kondo, Kan Yonemori, Atsuko Kawasaki, Kyoko Satake, et al. Correction to: Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer chemotherapy and pharmacology. 2024. 94. 3. 491-491
Pierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, Arnaud Pigneux, Junichiro Yuda, Mahipal Sinnollareddy, William R Henner, Diana Chen, Kevin J Freise, Rachel S Leibman, et al. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC. Expert review of anticancer therapy. 2024. 24. 9. 893-904
Takafumi Koyama, Kan Yonemori, Toshio Shimizu, Jun Sato, Shunsuke Kondo, Kazuki Sudo, Tatsuya Yoshida, Yuki Katsuya, Tatsuki Imaizumi, Masashi Enomoto, et al. Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors. Cancer research communications. 2024. 4. 9. 2349-2358
Toshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, Eriko Murakami, Ryota Shibaki, Toshio Shimizu, Yasuhiro Koh, Nobuyuki Yamamoto. Unsuccessful rechallenge with nivolumab in a patient with advanced non-small cell lung cancer who had a 6-year complete response and treatment-free period: Case report. Respirology case reports. 2024. 12. 9. e01401
Toshiaki Takakura, Toshio Shimizu, Nobuyuki Yamamoto. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy. Japanese journal of clinical oncology. 2024. 54. 8. 837-846

ｍore...

MISC (118)：

武田真幸, 中川和彦, 林秀敏, 岩朝勤, 川上尚人, 渡邉諭美, 山本昇, 米盛勧, 小山隆文, 佐藤潤, et al. ベンダムスチン塩酸塩経口剤(SyB C-0501)の進行性固形がん患者に対する第1相臨床試験. 日本癌治療学会学術集会抄録集. 2021. 59回. O13-5
清水俊雄. アジア圏における早期新薬開発共通標準化は可能なのか?. 腫瘍内科. 2021. 27. 6. 738-742
古川孝広, BARDIA Aditya, 清水俊雄, TOLCHER Anthony, SPIRA Alexander, 向原徹, LISBERG Aaron E., KROP Ian, PAPADOPOULOS Kyriakos P., HAMILTON Erika, et al. Datopotamab deruxtecanの第1相臨床試験TNBC中間結果. 日本癌治療学会学術集会(Web). 2021. 59th
小山隆文, 清水俊雄, 米盛勧, 小島勇貴, 松井直子, 大熊ひとみ, 野口瑛美, 須藤一起, 平川晃弘, 沖田南都子, et al. MDM2阻害剤を用いた内膜肉腫対象医師主導治験. 日本心臓血管外科学会学術総会抄録集. 2020. 50回. P23-3
小山隆文, 清水俊雄, 米盛勧, 小島勇貴, 松井直子, 大熊ひとみ, 野口瑛美, 須藤一起, 平川晃弘, 沖田南都子, et al. MDM2阻害剤を用いた内膜肉腫対象医師主導治験. 日本心臓血管外科学会学術総会抄録集. 2020. 50回. P23-3

ｍore...

Books (8)：

がん分子標的治療 2014年6月号(Vol.12 No.2)
メディカルレビュー社 2014
腫瘍内科第13巻第6号(2014年6月発行)
科学評論社 2014
日本臨床最新がん薬物療法学
日本臨床社 2014
腫瘍内科第13巻第1号(2014年1月発行)
科学評論社 2014
腫瘍内科第9巻第5号(2012年5月発行)
科学評論社 2012

ｍore...

Lectures and oral presentations (31)：

A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies
(The 73rd Annual Meeting of the Japanese Cancer Association (JCA) 2014)
Phase I study of YM155, selective survivin suppressant plus elrotnib in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC)
(The 12th Annual Meeting of Japanese Society of Medical Oncology 2014)
日本における早期探索臨床試験の推進について ~海外ベンチャー製薬企業主導型新薬第I相試験実施
(第22回日本乳癌学会学術集会 JBCS/JSMO Joint Symposium 2014)
Completed Phase I Trial of TLC388
(The 3rd Japan-Taiwan Phase I Oncology Conference (JTOPIC), Taipei, Taiwan 2014)
Infrastructural capability of investigator-initiated trials involving unapproved investigational drugs in Japan
(The 11th Annual Meeting of Japanese Society of Medical Oncology 2013)

ｍore...

Education (2)：

2003 - 2007 Kinki University Graduate School Medical Oncology
1993 - 1999 Kinki University Faculty of Medicine Faculty of Medicine

Professional career (1)：

博士(医学) (近畿大学)

Work history (8)：

2024/11 - 現在 Kansai Medical University Department of New Experimental Therapeutics Professor
2022/04 - 2024/10 Wakayama Medical University Associate Professor
2016/04 - 2022/03 National Cancer Center Hospital of Japan Department of Experimental Therapeutics Head of Physician (Early Phase 1 Drug Development Service)
2012/04 - 2016/03 Kindai University Faculty of Medicine Department of Medical Oncology Associate Professor
2010/01 - 2012/03 START (South Texas Accelerated Research Therapeutics) Phase I Center Clinical Fellow

Show all

Committee career (5)：

2022/04 - 現在 ESMO Targeted Anticancer Therapies (TAT) Phase 1 Scientific Committee
2020/04 - 現在 Asia Pacific Oncology Drug Development Consortium (APODDC) Executive Committee
2017/04 - 現在 The Consortium on Harmonization of Institutional Requirements for Clinical Research (CHAIR) Joint Scientific Committee Review Member for Phase 1 trials in Hong Kong, HKSAR IRB Member / Joint Scientific Committee Review Member for Phase 1 trials in Hong Kong, HKSAR
2013/04 - 現在日本臨床腫瘍学会学術企画委員
2012/04 - 現在日本臨床腫瘍学会協議員

Awards (2)：

2019/10 - Chinese Society of Clinical Oncology (CSCO) CSCO 2019 Travel Grant Award 受賞
2011/06 - ASCO ASCO 2011 Merit Award The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase 1 study

Association Membership(s) (8)：

日本製薬医学会 , THE JAPANESE SOCIETY OF CLINICAL PHARMACOLOGY AND THERAPEUTICS , THE JAPAN LUNG CANCER SOCIETY , JSMO(日本臨床腫瘍学会) , THE JAPANESE SOCIETY OF INTERNAL MEDICINE , ASCO(American Society of Clinical Oncology) , ESMO (European Society of Medical Oncology) , AACR (American Association of Cancer Research)

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page